The Patent Finder
TT

Tenaya Therapeutics, Inc.

First filing 2020
OverviewNotableFeesChangesFamiliesPatent listSources & methods

19 patents currently held

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Aug 2039. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Aug 2039
Next term end
10
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Mar 19, 2027
    The maintenance fee for Gene Therapy Vectors for Treating Heart Disease (US 11,759,531) comes due Mar 19, 2027. Unpaid by Sep 20, 2027, it lapses early.
  • 1 fee due Apr 10, 2027
    The maintenance fee for PLAKOPHILLIN-2 Gene Therapy Methods and Compositions (US 11,781,156) comes due Apr 10, 2027. Unpaid by Oct 12, 2027, it lapses early.
  • 1 fee due Aug 27, 2027
    The maintenance fee for Cardiac Cell Reprogramming with Myocardin and ASCL1 (US 11,913,012) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.
  • 1 fee due Sep 12, 2027
    The maintenance fee for Fluoroalkyl-Oxadiazoles and Uses Thereof (US 11,926,622) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 23, 2026

What they patent

The largest of its 10 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 11,015,211Cardiac Cell Reprogramming with Myocardin and ASCL1
In force
 · High confidence
In forceHigh confidence
US 11,913,012Cardiac Cell Reprogramming with Myocardin and ASCL1
In force
 · High confidence
In forceHigh confidence
US 12,168,778Cardiac Cell Reprogramming with Myocardin and ASCL1
In force
 · High confidence
In forceHigh confidence
US 12,104,165Adeno-Associated Virus with Engineered Capsid
In force
 · Medium confidence
In forceMedium confidence
US 11,578,066Fluoroalkyl-Oxadiazoles and Uses Thereof
In force
 · Medium confidence
In forceMedium confidence
US 11,926,622Fluoroalkyl-Oxadiazoles and Uses Thereof
In force
 · Medium confidence
In forceMedium confidence
US 12,201,617HDAC6 Inhibitors for Treatment of Metabolic Disease and Hfpef
In force
 · High confidence
In forceHigh confidence
US 12,312,345Fluoroalkyl-Oxadiazoles and Uses Thereof
In force
 · Low confidence
In forceLow confidence
US 11,129,908Gene Therapy Vectors for Treating Heart Disease
In force
 · High confidence
In forceHigh confidence
US 11,446,397Gene Therapy Vectors for Treating Heart Disease
In force
 · High confidence
In forceHigh confidence
10 of 19 patents shown.
Pro members see all 19.
Pro members: see all 19 patents
Also on record, not counted in the 19: 19 applications pending · 7 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited